Trevogrumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | growth differentiation factor 8 |
| Clinical data | |
| Other names | REGN1033 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6374H9884N1696O2018S46 |
| Molar mass | 144037.80 g·mol−1 |
Trevogrumab (INN; development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. It is often used with Garetosmab.
Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin (GDF8), a key negative regulator of skeletal muscle growth and mass. By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation.
This drug was developed by Regeneron Pharmaceuticals, Inc.